The sessions combine an artistic outlet with a place where breast cancer survivors and patients can share their experiences.

Olivia Munn has for more than a year been speaking out about the importance of a breast cancer risk assessment test that helped lead to her diagnosis in 2023, and she has now shared that that very same test also led to her mother’s breast cancer diagnosis.

Overall, this suggests that the cumulative risk of breast cancer before age 55 for women taking estrogen/progestin is about 4.5%, compared with 4.1% among women who never used hormone therapy and 3.6% for those who used unopposed estrogen therapy, researchers said.

Associations between hormone therapy and young-onset breast cancer (diagnosed at younger than 55 years) vary, according to a study published online in the July issue of The Lancet Oncology. Katie M. O'Brien,

Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Researchers discovered that

Decision-making was influenced by patient values and did not vary by stage, race and ethnicity, or demographics.

When offered the opportunity to participate in clinical trials, patients with breast cancer across racial and ethnic groups are equally likely to do so, according to a recent survey.

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based tests to inform decisions about adjuvant chemotherapy for patients with a certain type of breast cancer,

NIH study could help to guide clinical recommendations for hormone therapy use among women under 55 years old.